Home › Atrial Fibrillation › NCT06308094
320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
Who can join
Ages 21 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients must be at least 21 years old at the time of enrollment. * Patients must be able to give informed consent. * Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF). * Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol. * Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists Exclusion Criteria: * Known allergy to iodinated contrast media. * Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula). * Patients with a positive urine or serum pregnancy test will be excluded from this study. * Patients with heart transplantation. * Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm. * Presence of any other history or condition that the investigator feels would be problematic. * Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT. * Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal. * Patients with severe claustrophobia.
About the study
This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment strategies.
What is being tested
- CT (diagnostic test)
Sponsor: Johns Hopkins University · Participants: 100 · Started: Apr 10, 2025
Contact the study team
- Konstantinos Aronis, MD PHD · Phone: 2017169226
Official record on ClinicalTrials.gov — NCT06308094
Locations in the U.S.
| Maryland | Johns Hopkins Hospital, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.